Omnicell, Inc. (NASDAQ:OMCL) Short Interest Update

Omnicell, Inc. (NASDAQ:OMCL) was the target of a large growth in short interest in the month of November. As of November 30th, there was short interest totalling 2,120,000 shares, a growth of 55.9% from the November 15th total of 1,360,000 shares. Based on an average daily volume of 572,300 shares, the days-to-cover ratio is currently 3.7 days.

Omnicell Trading Up 0.1 %

OMCL traded up $0.05 during midday trading on Friday, reaching $46.01. The company’s stock had a trading volume of 296,981 shares, compared to its average volume of 535,995. The company has a fifty day simple moving average of $45.32 and a 200 day simple moving average of $39.04. The stock has a market cap of $2.13 billion, a P/E ratio of -117.97, a PEG ratio of 35.72 and a beta of 0.77. Omnicell has a twelve month low of $25.12 and a twelve month high of $55.74.

Insider Activity at Omnicell

In related news, Director Mark W. Parrish sold 12,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $47.30, for a total value of $567,600.00. Following the completion of the transaction, the director now owns 58,427 shares of the company’s stock, valued at approximately $2,763,597.10. This trade represents a 17.04 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 2.64% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Omnicell

Several hedge funds and other institutional investors have recently modified their holdings of OMCL. Pacer Advisors Inc. boosted its holdings in Omnicell by 32.6% in the 2nd quarter. Pacer Advisors Inc. now owns 2,070,434 shares of the company’s stock valued at $56,047,000 after purchasing an additional 508,789 shares during the period. Dimensional Fund Advisors LP raised its position in shares of Omnicell by 0.3% during the second quarter. Dimensional Fund Advisors LP now owns 1,180,503 shares of the company’s stock valued at $31,955,000 after buying an additional 3,570 shares during the last quarter. Victory Capital Management Inc. lifted its stake in shares of Omnicell by 11,982.3% in the third quarter. Victory Capital Management Inc. now owns 1,148,426 shares of the company’s stock valued at $50,071,000 after buying an additional 1,138,921 shares during the period. ArrowMark Colorado Holdings LLC grew its position in Omnicell by 27.1% during the third quarter. ArrowMark Colorado Holdings LLC now owns 1,140,873 shares of the company’s stock worth $49,742,000 after buying an additional 243,353 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in Omnicell by 0.3% during the third quarter. Geode Capital Management LLC now owns 1,104,745 shares of the company’s stock valued at $48,176,000 after acquiring an additional 2,877 shares during the period. Institutional investors and hedge funds own 97.70% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently commented on the company. Barclays raised their target price on Omnicell from $39.00 to $58.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. JPMorgan Chase & Co. lifted their target price on Omnicell from $37.00 to $44.00 and gave the company a “neutral” rating in a research note on Thursday, November 21st. Bank of America reissued a “neutral” rating and issued a $57.00 price target (up from $44.00) on shares of Omnicell in a research report on Thursday, October 31st. StockNews.com downgraded shares of Omnicell from a “buy” rating to a “hold” rating in a research report on Tuesday, December 10th. Finally, Craig Hallum increased their target price on shares of Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. Five investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $52.00.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.